Kuros Biosciences AG (CSBTF)
| Previous close | 1.9200 |
| Open | 1.9200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.9200 - 1.9200 |
| 52-week range | 1.9200 - 3.1000 |
| Volume | |
| Avg. volume | 63 |
| Market cap | 63.515M |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2380 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules • $2.5 million of milestone to be paid to XOMA Corporation under royalty agreement SCHLIEREN (ZURICH), Switzerland, June 02, 2022 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, notes the completion of the acquisition of Checkmate Pharmaceuticals (NASDAQ: CMPI) by Regeneron Pharmaceuticals (NASDAQ: REGN). The completion triggers a $5 million milestone paym
- GlobeNewswire
Kuros Biosciences’s MagnetOs Granules Cleared by FDA for Expanded Spinal Indications
Rare clearance for bone graft for standalone use in spine based on human clinical dataClearance attained with evidence from Level 1 randomized controlled trialPositions MagnetOs above most other 510(k)-cleared bone grafts on the market SCHLIEREN (ZURICH), Switzerland, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that its MagnetOs Granules has been cleared by the U.S. Food and Drug Administrati
- GlobeNewswire
Kuros Biosciences Reports Continued Increase in MagnetOs U.S. Sales
Ad hoc announcement pursuant to Article 53 of the SIX listing rulesMagnetOs U.S. YTD sales increase 119% in 2021 compared to 2020Kuros expanding MagnetOs range to increase perioperative solutions for surgeons SCHLIEREN (ZURICH), Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, today provided an update on its commercial activities. Direct sales of MagnetOs in the U.S. continued to accelerate in Q3 202
